Lexaria Bioscience Net Income 2018-2021 | LEXX

Lexaria Bioscience net income from 2018 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Lexaria Bioscience Annual Net Income
(Millions of US $)
2020 $-4
2019 $-4
2018 $-7
Lexaria Bioscience Quarterly Net Income
(Millions of US $)
2021-05-31 $-3
2021-02-28 $0
2020-11-30 $-1
2020-08-31 $-1
2020-05-31 $-1
2020-02-29 $-1
2019-11-30 $-1
2019-08-31 $-1
2019-05-31 $-1
2019-02-28 $-1
2018-11-30 $-1
2018-08-31 $-1
2018-05-31 $-3
2018-02-28 $-1
2017-11-30 $-1
2017-08-31
2017-05-31 $-0
2017-02-28 $-0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.034B $0.000B
Lexaria Bioscience Corp. provides drug delivery platforms. Its patented DehydraTECH(TM) drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. Lexaria Bioscience Corp. is based in Kelowna, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.038B 8.59
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.127B 20.54
Biohaven Pharmaceutical Holding (BHVN) United States $8.605B 0.00
Emergent Biosolutions (EBS) United States $2.673B 6.45
Arcus Biosciences (RCUS) United States $2.441B 0.00
Myovant Sciences (MYOV) United Kingdom $1.860B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.754B 0.00
Zymeworks (ZYME) Canada $1.075B 0.00
Ambrx Biopharma (AMAM) United States $0.524B 0.00
SQZ Biotechnologies (SQZ) United States $0.335B 0.00
Enzo Biochem (ENZ) United States $0.158B 15.48